Orwin John A 4

What Happened John A. Orwin, a member of Travere Therapeutics' board of directors, was granted a total of 16,000 shares on 2026-05-19: 4,000 outright stock shares and 12,000 derivative shares reported at $0.00 (awards, not purchases). The filings list the per-share price as $0.00 and show $0 cash paid — these were compensation awards, not open-market purchases.

Key Details

• Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (timely within the usual 2-business-day window).
• Grants: 4,000 shares (direct award) and 12,000 derivative shares (award) — both reported at $0.00.
• Shares owned after transaction: not specified in the provided excerpt.
• Footnotes: F1 — automatic equity grant under the Issuer's 2018 Equity Incentive Plan as part of the non‑employee director compensation program. F2 — the derivative equity award vests over a one‑year period.
• Filing status: timely (no late filing flag indicated).

Context These awards appear to be routine non‑employee director compensation (automatic grants) rather than a purchase or sale that would signal a direct market bet. The 12,000 derivative shares vest over one year (per the footnote), meaning they are subject to time-based vesting before becoming fully owned/transferable. Awards like this are common for board members and should be viewed as standard compensation rather than an immediate buy or sell signal.